Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Engineered immune cells get a helping hand in a new clinical trial for multiple myeloma patients.
Recent legislation may help narrow the gap between FDA approval of cancer medications for adults and children.
Scientists emphasize using data and analyses from completed and ongoing trials to gain a better understanding of patient outcomes.
Forty-five percent of 182 phase 3 clinical trials between 1980 and 2017 influenced guideline care or new drug approvals.
Surprising new research suggests why 97% of cancer drugs in clinical trials fail to stop cancer in patients and never make it to market.
Gaby Kressly, now in her early 80s, was diagnosed with ovarian cancer in 2016.
Funding will help enroll more minority and underserved patients in cancer clinical trials across Louisiana and Mississippi.
A related study finds patient and provider perceptions about barriers to trial participation are not in sync.
The study raises concerns about the effectiveness of cancer drugs, as genetic differences may affect how someone responds to a drug.
The latest research on healthy life and prevention, improving outcomes, reducing side effects and getting the best precision medicine.
An interview with Michael Kaplan, president and CEO of the Melanoma Research Alliance, about curing the deadliest skin cancer
The answer may lie in the damage radiation therapy does to the immune system.
New research asks if an alternative dosing schedule can produce the same effects with fewer side effects.
Engineered T cells kept leukemia from returning in 12 high-risk patients.
National Cancer Institute’s comparative oncology studies
The results from an innovative, “virtual” clinical trial were presented at the 2019 ASCO Annual Meeting.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.